Analysts expect Oxford Immunotec Global PLC (NASDAQ:OXFD) to post earnings per share of ($0.05) for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Oxford Immunotec Global’s earnings. The highest EPS estimate is ($0.02) and the lowest is ($0.09). Oxford Immunotec Global reported earnings per share of ($0.25) during the same quarter last year, which would indicate a positive year over year growth rate of 80%. The company is expected to announce its next earnings report before the market opens on Tuesday, August 6th.
According to Zacks, analysts expect that Oxford Immunotec Global will report full-year earnings of ($0.24) per share for the current financial year, with EPS estimates ranging from ($0.27) to ($0.19). For the next fiscal year, analysts anticipate that the company will report earnings of ($0.16) per share, with EPS estimates ranging from ($0.20) to ($0.13). Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that cover Oxford Immunotec Global.
Oxford Immunotec Global (NASDAQ:OXFD) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.14. The company had revenue of $14.79 million during the quarter, compared to the consensus estimate of $13.74 million. Oxford Immunotec Global had a net margin of 172.27% and a return on equity of 13.56%. The company’s quarterly revenue was up 26.6% on a year-over-year basis. During the same quarter last year, the firm posted ($0.40) EPS.
Institutional investors and hedge funds have recently modified their holdings of the stock. Squarepoint Ops LLC lifted its holdings in shares of Oxford Immunotec Global by 36.1% in the 4th quarter. Squarepoint Ops LLC now owns 19,303 shares of the company’s stock worth $247,000 after purchasing an additional 5,120 shares in the last quarter. Marshall Wace LLP bought a new position in shares of Oxford Immunotec Global in the 1st quarter worth $1,185,000. Millennium Management LLC lifted its holdings in shares of Oxford Immunotec Global by 117.2% in the 4th quarter. Millennium Management LLC now owns 117,914 shares of the company’s stock worth $1,507,000 after purchasing an additional 63,617 shares in the last quarter. Northern Trust Corp lifted its holdings in shares of Oxford Immunotec Global by 0.7% in the 4th quarter. Northern Trust Corp now owns 290,723 shares of the company’s stock worth $3,715,000 after purchasing an additional 2,113 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of Oxford Immunotec Global by 15.9% in the 4th quarter. Geode Capital Management LLC now owns 101,930 shares of the company’s stock worth $1,302,000 after purchasing an additional 13,974 shares in the last quarter. Institutional investors own 91.19% of the company’s stock.
Shares of OXFD stock traded up $0.17 during trading hours on Friday, hitting $13.21. 149,349 shares of the company were exchanged, compared to its average volume of 185,511. The stock has a market capitalization of $343.44 million, a price-to-earnings ratio of 25.90 and a beta of 0.33. Oxford Immunotec Global has a fifty-two week low of $11.88 and a fifty-two week high of $19.19. The company has a debt-to-equity ratio of 0.04, a quick ratio of 12.03 and a current ratio of 12.60. The company’s 50 day simple moving average is $13.49.
About Oxford Immunotec Global
Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States. It develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions.
Further Reading: Why do analysts give a neutral rating?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.